Recent Updates
Recently added Catalysts
USNA Negative Sentiment

USANA Health Sciences Reports Second Quarter 2026 Results

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: USANA Health Sciences reported a challenging second quarter for 2026, with net sales declining to $223 million from $236 million in the same period last year. The company experienced a net loss of $(21.4) million, which included a non-cash impairment charge of $29.1 million. This contrasts sharply with the previous year's net earnings of $9.7 million, resulting in a diluted EPS of $(1.16).

Market Sentiment Analysis

CONCERNS & RISKS

  • Net sales decreased from $236 million to $223 million.
  • The company reported a net loss of $(21.4) million compared to net earnings of $9.7 million.
  • Diluted EPS fell to $(1.16) from $0.52.

Full Press Release Details

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 4, 2026. Key Financial Results Second Quarter 2026 vs. Second Quarter 2025 Net sales of $223 million versus $236 million. Net loss of $(21.4) million, which includes an estimated preliminary non-cash impairment charge(3) of $29.1 million, versus net earnings of $9.7 million. Diluted EPS of $(1.16) as compared with $0.52. Adjusted diluted EPS(1) of

Frequently Asked Questions

What were USANA's net sales for Q2 2026?

USANA's net sales for Q2 2026 were $223 million.

How much was USANA's net loss in Q2 2026?

USANA reported a net loss of $(21.4) million in Q2 2026.

What was USANA's diluted EPS for Q2 2026?

The diluted EPS for USANA in Q2 2026 was $(1.16).

How did Q2 2026 earnings compare to Q2 2025?

In Q2 2025, USANA had net earnings of $9.7 million.

ShareAdd on Google
Tags: USNA Viatris Investor Conferences Healthcare USANA financial results net loss Q2 2026 health sciences
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$163M liquidity · $0M/mo burn
Low dilution risk